Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Screening of traditional Chinese medicine monomers as ribonucleotide reductase M2 inhibitors for tumor treatment.
World J Clin Cases
November 2022
School of Basic Medicine, North Sichuan Medical College, Nanchong 637000, Sichuan Province, China.
Background: Ribonucleotide reductase (RR) is a key enzyme in tumor proliferation, especially its subunit-RRM2. Although there are multiple therapeutics for tumors, they all have certain limitations. Given their advantages, traditional Chinese medicine (TCM) monomers have become an important source of anti-tumor drugs.
View Article and Find Full Text PDFA novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway.
Cancer Cell Int
May 2021
CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China.
Background: Multiple myeloma (MM) is a highly aggressive and incurable clonal plasma cell disease with a high rate of recurrence. Thus, the development of new therapies is urgently needed. DCZ0805, a novel compound synthesized from osalmide and pterostilbene, has few observed side effects.
View Article and Find Full Text PDFAnti-DLBCL efficacy of DCZ0825 in vitro and in vivo: involvement of the PI3K‒AKT‒mTOR/JNK pathway.
Acta Biochim Biophys Sin (Shanghai)
April 2021
Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Article Synopsis
- DLBCL is the most common non-Hodgkin lymphoma, and there's a need for new treatments due to relapses and resistance to current therapies.
- DCZ0825, a new compound derived from pterostilbene and osalmide, shows strong anti-tumor effects against DLBCL cell lines by inducing cell apoptosis and arresting the cell cycle.
- The compound works by targeting specific pathways (PI3K-AKT-mTOR/JNK) and demonstrates effectiveness in vivo with minimal toxicity to vital organs, suggesting its potential as an innovative treatment for DLBCL.
Identification of osalmid metabolic profile and active metabolites with anti-tumor activity in human hepatocellular carcinoma cells.
Biomed Pharmacother
October 2020
State Key Laboratory for Diagnosis and Treatment of Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang 310000, People's Republic of China. Electronic address:
Backgrounds: Ribonucleotide reductase (RR) catalyzes the essential step in the formation of all four deoxynucleotides. Upregulated activity of RR plays an active role in tumor progression. As the regulatory subunit of RR, ribonucleotide reductase subunit M2 (RRM2) is regarded as one of the effective therapeutic targets for DNA replication-dependent diseases, such as cancers.
View Article and Find Full Text PDFGlycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma.
J Cancer
June 2020
CAS Key Laboratory of Receptor Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Multiple myeloma (MM) is a highly invasive and incurable plasma cell malignant disease with frequent recurrence. DCZ0801 is a natural compound synthesized from osalmide and pterostilbene and has few adverse effects. Here, we aimed to observe the therapeutic effects of DCZ0801 on myeloma cells and clarify the specific molecular mechanism underlying its anti-tumor activity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!